Current Medications for ALS Treatment
Limited Options Available
The treatment landscape for amyotrophic lateral sclerosis (ALS) remains challenging due to a complex and not fully understood mechanism of action. Presently, only two medications have received FDA approval for this neurodegenerative disease, which is known for causing progressive muscle weakness and declining motor function. In advanced stages, patients often face severe breathing difficulties, with a median survival time of two to three years following disease onset. Unfortunately, no cure exists for ALS.
Approved Drugs and Their Effects
The two FDA-approved drugs for ALS are riluzole and edaravone. Riluzole has been shown to extend survival by several months, while edaravone may enhance functional scores among specific patient groups. Additionally, rasagiline, a medication recognized for its therapeutic effects in Parkinson’s disease, has demonstrated potential benefits in ALS research by inhibiting the breakdown of dopamine and serotonin. Studies in mice have indicated that rasagiline could lead to improved survival rates.
Investigating Rasagiline as an Add-On Therapy
Clinical Trial Overview
A multicentre, randomized, controlled phase-2 trial was conducted in Germany to evaluate the efficacy of rasagiline as an adjunct treatment to riluzole. The findings from this trial were published in The Lancet Neurology. The study involved patients who had been diagnosed with ALS for 6 to 36 months and had been on a daily regimen of riluzole for a minimum of three months. Participants were randomly assigned to receive either daily doses of riluzole combined with rasagiline or a placebo over an 18-month treatment period. Clinical and physical assessments were conducted at intervals of 2, 6, 12, and 18 months, with the primary outcome being survival rates.
Study Results
The trial enrolled a total of 252 patients. Ultimately, no significant differences in survival were observed between the rasagiline and placebo groups. At the conclusion of the 36-month period, the survival rate stood at 53% for the placebo group and 43% for those receiving the rasagiline treatment. The incidence of adverse events was comparable across both groups, with the majority of adverse effects attributed to the progression of ALS itself.
Future Considerations for Research
Analyzing Disease Progression
An exploratory analysis indicated that rasagiline might have slowed disease progression during the initial six months of treatment. However, this observation could be influenced by a higher proportion of rapidly progressing patients being placed in the placebo group. The authors of the study recommend that future trials should account for the disease progression rate when assigning groups to better assess the impact of rasagiline.
Potential for Disease-Modifying Effects
If rasagiline is confirmed to possess disease-modifying properties within the first six months of treatment, it would represent a significant advancement in the limited therapeutic options currently available for ALS.
References
Ludolph AC et al. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol. 2018 Aug;17(8):681-688. doi: 10.1016/S1474-4422(18)30176-5. Epub 2018 Jun 19.